Hello everyone, I am Jill Coe. I'm a biologist from the French group and I'm going to talk about my presentation at IMS 2024 meeting in Rio this morning. I've been asked to talk about the new IMS high-risk genomic definition. Actually, until now, high-risk cytogenetics is to have a DELESION 17P, to have a T414 or to have a T1416, which are the three high-risk abnormalities in myeloma. And we felt that in this new era of triplet, quadriplet treatments, with the big progress, therapeutic progress that has been made in the last decades, this traditional cytogenetic factor did not capture anymore the prognosis accurately. So we worked on a large cohort of patients to understand the interaction between some factors, which are the real high-risk factors. And we had a debate in Barcelona one year ago. It was the IMS panel. And at the end of the day, we had a consensus definition on high risk, which is the following. A high-risk patient now is a patient with a DELESION 17P in more than 20% of plasma cell or a patient with a TP53 mutation or a patient with DELESION 1P32 but biallelic. This is a double DELESION. Or a high-risk patient is a patient with the association of at least two intermediate factors. What are these intermediate factors? This is T1416, T414, T1420, 1Q gain and monoallelic DELESION 1P32. So it can look a very complicated new definition, but this is a reality of myeloma. This is a complex disease, very heterogeneous. And we needed to have a clear consensus to speak the same language between countries when we talk about high-risk patients. If France and England and German and American don't talk about the same patient, we can't make progress. So now we have this consensus definition and we recommend to use it in all ongoing and forward clinical trials and in routine practice.